Turkish BRIEF version of the Hammersmith Infant Neurological Examination (HINE)

Turkish Version of the BRIEF-Hammersmith Infant Neurological Examination (HINE) With High-Risk of Infants: A Study of Validity and Reliability

This project tests a short Turkish BRIEF-HINE neurological screening for infants who are at high risk of neurodevelopmental problems to see if it works well in routine clinics.

Quick facts

• Study type: Observational
• Enrollment: 120 (estimated)
• Ages: 3 Months to 12 Months
• Sex: All
• Sponsor: Kahramanmaras Sutcu Imam University (other)
• Locations: 1 site (Kahramanmaraş, Onikişubat)
• Trial ID: NCT07182474 on ClinicalTrials.gov

What this trial studies

This observational project implements a Turkish translation of the BRIEF-HINE and uses it with infants identified as high risk for neurological impairment. Clinicians will administer the brief HINE during routine follow-up visits and collect findings alongside standard clinical information and outcomes. The study will measure the tool's reliability, feasibility in busy clinics, and ability to flag infants who need early intervention. The goal is to produce a validated, shorter neurological exam that is practical for use in resource-limited follow-up programs.

Who should consider this trial

Good fit: Infants considered high risk for cerebral palsy or neurodevelopmental problems — for example those with prematurity (including birth before 32 weeks), IVH/PVL, HIE, severe jaundice (kernicterus), perinatal stroke or asphyxia, prolonged mechanical ventilation, sepsis, NEC, RDS/BPD, multiple births, significant growth restriction or prolonged metabolic disturbances — are eligible.

Not a fit: Infants without neurological risk factors or children who require comprehensive diagnostic neurodevelopmental evaluations rather than a brief screening are unlikely to benefit from this short tool alone.

Why it matters

Potential benefit: If successful, the tool could enable faster neurological screening and earlier referral to therapy for high-risk infants in Turkey and similar settings.

How similar studies have performed: The full HINE and several shorter HINE-based screenings have shown good predictive value for neuromotor outcomes like cerebral palsy in other countries, but a validated Turkish BRIEF-HINE is novel.

Eligibility criteria

Inclusion Criteria:

* Infants with high risk of CP: Periventricular hemorrhage, intracranial hemorrhage grade 2, 3, 4, cystic PVL, stage 3 hypoxic ischemic encephalopathy, neonatal bilirubin encephalopathy (kernicterus), perinatal stroke, perinatal asphyxia, respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD) and infants receiving long-term O₂ support, sepsis due to gram-negative bacteria, necrotizing enterocolitis (NEC), infantile apnea, those with a low 5-minute Apgar score (3 and below), those diagnosed with intrauterine growth retardation, multiple births (twins, triplets), preterm infants with retinopathy of prematurity (ROP), infants with prolonged severe hypoglycemia and hypocalcemia, (small for gestational age (SGA), less than the 3rd percentile) or large for gestational age (large for gestational age (LGA), less than the 97th percentile). (large) babies, babies receiving mechanical ventilation for more than 24 hours, babies born at less than 32 weeks of gestation and weighing less than 1500 grams.

Exclusion Criteria:

* Infants with any known orthopedic, systemic disease or neurological diagnosis other than CP

Where this trial is running

Kahramanmaraş, Onikişubat

• Kahramanmaraş Sütçü imam University — Kahramanmaraş, Onikişubat, Turkey (Türkiye) (RECRUITING)

Study contacts

• Study coordinator: Hatice adıgüzel tat, Associate Proffessor

Conditions: Pediatrics, Neurological Abnormality, Neurodevelopment Outcome